Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methadone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Methadone | DRUG | - |
Inclusion Criteria: * \> 18 years of age * Experiences episodes of breakthrough pain which respond to opioid therapy * Controlled baseline pain * Cognitive status sufficient for accurate completion of assessment form * Willing to provide written informed consent * Ability to hold a volume of 1 cc o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Methadone is being studied for the management of cancer breakthrough pain. It is an investigational small molecule in Phase 1 clinical development for this oncology indication. The drug is administered sublingually and has been evaluated in a completed clinical trial involving patients with cancer-related pain.
Methadone is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is conducting clinical research on this drug for cancer breakthrough pain. Avalon GloboCare Corp. trades under the ticker symbol ALBT.
Methadone is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the management of cancer breakthrough pain, and its Phase 1 trial has been completed.
Methadone has one completed clinical trial registered as NCT00125294, titled 'Sublingual Methadone for the Management of Cancer Breakthrough Pain.' This Phase 1 study enrolled 10 participants with cancer and pain. The trial was uncontrolled and not randomized or double-blinded.
Methadone is an opioid analgesic that works by binding to opioid receptors in the central nervous system, thereby altering the perception of and response to pain. It is being studied for its ability to manage breakthrough pain in cancer patients when administered sublingually.